Syndax Pharmaceuticals
SNDX
189 hedge funds and large institutions have $2.15B invested in Syndax Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 82 increasing their positions, 54 reducing their positions, and 18 closing their positions.
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
52% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 54
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
10% more capital invested
Capital invested by funds: $1.95B → $2.15B (+$197M)
7% more funds holding
Funds holding: 177 → 189 (+12)
6% more call options, than puts
Call options by funds: $8.74M | Put options by funds: $8.25M
6.01% less ownership
Funds ownership: 112.28% → 106.26% (-6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$21.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$15M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$34.3M |
| 2 |
Morgan Stanley
New York
|
-$33.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$25.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.1M |
| 5 |
Millennium Management
New York
|
-$5.82M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
201
Bayesian Capital Management
Brooklyn,
New York
| – | -$327K | -15,116 | Closed |
|
|
VF
202
Virtu Financial
New York
| – | -$258K | -11,948 | Closed |
|
203
Capstone Investment Advisors
New York
| – | -$235K | -10,895 | Closed |
|
|
GWS
204
Glassman Wealth Services
Vienna,
Virginia
| – | -$2.14K | -99 | Closed |
|
205
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1.08K | -50 | Closed |
|
206
AssetMark Inc
Concord,
California
| – | -$216 | -10 | Closed |
|
SNDX Hedge Fund Activity: Q1 2024 in Review
189 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2024, worth a combined $2.15B — up 10% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SNDX positions and 18 closed out — a net gain of 12 holders — while 82 added to existing stakes and 54 trimmed.
The largest buyer was Iron Triangle Partners, opening a new position worth an estimated $21.7M. The largest seller was Avidity Partners Management, cutting an estimated $34.3M.
- 189 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2024, up from 177 in Q4 2023.
- Funds reported $2.15B of Syndax Pharmaceuticals stock for Q1 2024, up 10% quarter-over-quarter.
- 30 funds opened new Syndax Pharmaceuticals positions in Q1 2024 and 18 closed out, a net change of +12 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2024 was Iron Triangle Partners, an estimated $21.7M added.
- The largest Syndax Pharmaceuticals seller in Q1 2024 was Avidity Partners Management, an estimated $34.3M sold.
Based on aggregated 13F filings for Q1 2024.